A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1186/s13075-014-0415-2
Published Online: 2014-08-29
Published Print: 2014-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Greenwald, Maria
Szczepanski, Leszek
Kennedy, Alastair
Veenhuizen, Melissa
Komocsar, Wendy J
Polasek, Emery
Guerrettaz, Kelly
Berclaz, Pierre-Yves
Lee, Chin
License valid from 2014-08-01